Dynamic variables: novel and perhaps better predictors of progression in benign prostatic hyperplasia.
Clinical Effectiveness Unit, The Royal College of Surgeons of England, and The Institute of Urology and Nephrology, University College London, London, UK.
James N
JN
Armitage
Mark
M
Emberton
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D018450:Disease Progression; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D011799:Quinazolines / Q000627:therapeutic use*; D012307:Risk Factors; D014555:Urination Disorders / Q000188:drug therapy*
D000317:Adrenergic alpha-Antagonists; D011799:Quinazolines; C047638:alfuzosin